NASDAQ:ADMS - Adamas Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$29.35 +0.12 (+0.41 %)
(As of 05/28/2018 06:00 AM ET)
Previous Close$29.35
Today's Range$28.76 - $29.49
52-Week Range$13.50 - $44.00
Volume318,214 shs
Average Volume709,976 shs
Market Capitalization$791.93 million
P/E Ratio-7.39
Dividend YieldN/A
Beta1.55

About Adamas Pharmaceuticals (NASDAQ:ADMS)

Adamas Pharmaceuticals logoAdamas Pharmaceuticals, Inc. discovers, develops, and sells therapies for chronic neurologic disorders. The company's approved/commercial product is GOCOVRI, an amantadine therapy for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease. Its partnered approved/commercial products include Namzaric (memantine hydrochloride extended-release and donepezil hydrochloride) capsules; and Namenda XR (memantine hydrochloride) extended release capsules for the treatment of moderate to severe Alzheimer's disease. The company's product candidates under development includes ADS-5102, which is in Phase III clinical trials for the treatment of multiple sclerosis walking impairment; and in Phase II clinical trials for additional indications, such as the treatment of wearing OFF and delaying motor complications in Parkinson's disease, tardive dyskinesia, Huntington's chorea, and Tourette syndrome, as well as non-motor disorders consisting of depression, and anti-psychotic induced weight gain. Its products under development also includes ADS-4101, a modified-release lacosamide that has completed Phase I clinical study for the treatment of partial onset seizures in patients with epilepsy. The company was formerly known as NeuroMolecular Pharmaceuticals, Inc. and changed its name to Adamas Pharmaceuticals, Inc. in July 2007. Adamas Pharmaceuticals, Inc. was founded in 2000 and is headquartered in Emeryville, California.

Receive ADMS News and Ratings via Email

Sign-up to receive the latest news and ratings for ADMS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ADMS
CUSIPN/A
Phone510-450-3500

Debt

Debt-to-Equity Ratio0.63
Current Ratio9.85
Quick Ratio9.73

Price-To-Earnings

Trailing P/E Ratio-7.39
Forward P/E Ratio-5.15
P/E GrowthN/A

Sales & Book Value

Annual Sales$570,000.00
Price / Sales1,389.23
Cash FlowN/A
Price / CashN/A
Book Value$2.90 per share
Price / Book10.12

Profitability

EPS (Most Recent Fiscal Year)($3.97)
Net Income$-89,490,000.00
Net Margins-3,470.97%
Return on Equity-101.94%
Return on Assets-56.21%

Miscellaneous

Employees147
Outstanding Shares26,980,000

Adamas Pharmaceuticals (NASDAQ:ADMS) Frequently Asked Questions

What is Adamas Pharmaceuticals' stock symbol?

Adamas Pharmaceuticals trades on the NASDAQ under the ticker symbol "ADMS."

How were Adamas Pharmaceuticals' earnings last quarter?

Adamas Pharmaceuticals Inc (NASDAQ:ADMS) announced its quarterly earnings results on Thursday, May, 3rd. The specialty pharmaceutical company reported ($1.35) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.37) by $0.02. The specialty pharmaceutical company had revenue of $2.55 million for the quarter, compared to the consensus estimate of $1.71 million. Adamas Pharmaceuticals had a negative return on equity of 101.94% and a negative net margin of 3,470.97%. View Adamas Pharmaceuticals' Earnings History.

What price target have analysts set for ADMS?

11 brokerages have issued 1 year price targets for Adamas Pharmaceuticals' stock. Their forecasts range from $31.00 to $55.00. On average, they anticipate Adamas Pharmaceuticals' stock price to reach $43.00 in the next year. View Analyst Ratings for Adamas Pharmaceuticals.

What are Wall Street analysts saying about Adamas Pharmaceuticals stock?

Here are some recent quotes from research analysts about Adamas Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Adamas Pharmaceuticals, Inc. is a specialty pharmaceutical company driven to improve the lives of those affected by chronic disorders of the central nervous system. The company seeks to achieve this by modifying the pharmacokinetic profiles of approved drugs to create novel therapeutics for use alone and in fixed-dose combination products. Adamas is currently developing ADS-5102, its lead wholly-owned product candidate, for the treatment of levodopa-induced dyskinesia (LID) associated with Parkinson's disease and for the treatment of major symptoms associated with multiple sclerosis in patients with walking impairment. The company's portfolio also includes Namzaric and Namenda XR, two approved products with Forest Laboratories Holdings Limited, an indirect wholly-owned subsidiary of Allergan plc. Forest is responsible for marketing both products in the United States under an exclusive license from Adamas. " (5/9/2018)
  • 2. Mizuho analysts commented, "We believe Adamas is building a solid case for the importance of Gocovri within the Parkinson’s treatment paradigm, thereby increasing the company’s attractiveness as a takeout candidate longer-term. We reiterate our Buy rating and $49 PT." (4/20/2018)

Who are some of Adamas Pharmaceuticals' key competitors?

Who are Adamas Pharmaceuticals' key executives?

Adamas Pharmaceuticals' management team includes the folowing people:
  • Dr. Gregory T. Went, Co-Founder, Chairman & CEO (Age 54)
  • Ms. Jennifer J. Rhodes, Chief Bus. Officer, Gen. Counsel, Chief Compliance Officer & Corp. Sec. (Age 48)
  • Dr. Rajiv Patni, Chief Medical Officer (Age 49)
  • Mr. Alfred G. Merriweather, Chief Financial Officer (Age 64)
  • Mr. Richard A. King, Chief Operating Officer (Age 53)

Has Adamas Pharmaceuticals been receiving favorable news coverage?

Media headlines about ADMS stock have been trending somewhat positive on Monday, Accern Sentiment reports. The research group ranks the sentiment of news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Adamas Pharmaceuticals earned a coverage optimism score of 0.07 on Accern's scale. They also assigned news articles about the specialty pharmaceutical company an impact score of 46.06 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next few days.

Who are Adamas Pharmaceuticals' major shareholders?

Adamas Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include STATE STREET CORP (10.46%), Point72 Asset Management L.P. (7.55%), BlackRock Inc. (5.50%), BROADFIN CAPITAL, LLC (5.37%), Sphera Funds Management LTD. (1.24%) and JPMorgan Chase & Co. (0.90%). Company insiders that own Adamas Pharmaceuticals stock include Christopher B Prentiss, Great Point Partners Llc, Gregory T Went, Ix Lp Mdv, Jennifer J Rhodes, Rajiv Patni, William J Dawson and William W Ericson. View Institutional Ownership Trends for Adamas Pharmaceuticals.

Which institutional investors are selling Adamas Pharmaceuticals stock?

ADMS stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Point72 Asset Management L.P., Citigroup Inc., JPMorgan Chase & Co., Opus Point Partners Management LLC, New York State Common Retirement Fund and Blair William & Co. IL. Company insiders that have sold Adamas Pharmaceuticals company stock in the last year include Christopher B Prentiss, Great Point Partners Llc, Gregory T Went, Jennifer J Rhodes and Rajiv Patni. View Insider Buying and Selling for Adamas Pharmaceuticals.

Which institutional investors are buying Adamas Pharmaceuticals stock?

ADMS stock was acquired by a variety of institutional investors in the last quarter, including Sphera Funds Management LTD., Kornitzer Capital Management Inc. KS, UBS Group AG, BlackRock Inc., Lord Abbett & CO. LLC, Oak Ridge Investments LLC, Deltec Asset Management LLC and SCP Investment LP. Company insiders that have bought Adamas Pharmaceuticals stock in the last two years include Ix Lp Mdv and William W Ericson. View Insider Buying and Selling for Adamas Pharmaceuticals.

How do I buy shares of Adamas Pharmaceuticals?

Shares of ADMS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Adamas Pharmaceuticals' stock price today?

One share of ADMS stock can currently be purchased for approximately $29.35.

How big of a company is Adamas Pharmaceuticals?

Adamas Pharmaceuticals has a market capitalization of $791.93 million and generates $570,000.00 in revenue each year. The specialty pharmaceutical company earns $-89,490,000.00 in net income (profit) each year or ($3.97) on an earnings per share basis. Adamas Pharmaceuticals employs 147 workers across the globe.

How can I contact Adamas Pharmaceuticals?

Adamas Pharmaceuticals' mailing address is 1900 POWELL ST. SUITE 750, EMERYVILLE CA, 94608. The specialty pharmaceutical company can be reached via phone at 510-450-3500 or via email at [email protected]


MarketBeat Community Rating for Adamas Pharmaceuticals (ADMS)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  257 (Vote Outperform)
Underperform Votes:  184 (Vote Underperform)
Total Votes:  441
MarketBeat's community ratings are surveys of what our community members think about Adamas Pharmaceuticals and other stocks. Vote "Outperform" if you believe ADMS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ADMS will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Adamas Pharmaceuticals (NASDAQ:ADMS) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
11 Wall Street analysts have issued ratings and price targets for Adamas Pharmaceuticals in the last 12 months. Their average twelve-month price target is $43.00, suggesting that the stock has a possible upside of 46.51%. The high price target for ADMS is $55.00 and the low price target for ADMS is $31.00. There are currently 11 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $43.00$43.00$46.00$42.00
Price Target Upside: 46.51% upside53.08% upside76.79% upside24.15% upside

Adamas Pharmaceuticals (NASDAQ:ADMS) Consensus Price Target History

Price Target History for Adamas Pharmaceuticals (NASDAQ:ADMS)

Adamas Pharmaceuticals (NASDAQ:ADMS) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/22/2018Piper Jaffray CompaniesSet Price TargetBuy$49.00LowView Rating Details
4/20/2018MizuhoReiterated RatingBuy$49.00MediumView Rating Details
4/4/2018Leerink SwannInitiated CoverageOutperform ➝ Outperform$31.00HighView Rating Details
3/27/2018Bank of AmericaInitiated CoverageBuy$39.00HighView Rating Details
2/25/2018Needham & Company LLCSet Price TargetBuy$40.00LowView Rating Details
2/23/2018Noble FinancialReiterated RatingBuyLowView Rating Details
2/21/2018William BlairReiterated RatingOutperformLowView Rating Details
12/13/2017CowenSet Price TargetBuy$55.00HighView Rating Details
11/29/2017Northland SecuritiesInitiated CoverageOutperform ➝ OutperformLowView Rating Details
10/30/2017Evercore ISIInitiated CoverageOutperformN/AView Rating Details
8/25/2017JMP SecuritiesReiterated RatingMkt Outperform ➝ Outperform$29.00 ➝ $33.00HighView Rating Details
7/25/2016Credit Suisse GroupReiterated RatingBuy$21.00N/AView Rating Details
(Data available from 5/28/2016 forward)

Earnings

Adamas Pharmaceuticals (NASDAQ:ADMS) Earnings History and Estimates Chart

Earnings by Quarter for Adamas Pharmaceuticals (NASDAQ:ADMS)

Adamas Pharmaceuticals (NASDAQ:ADMS) Earnings Estimates

2018 EPS Consensus Estimate: ($5.82)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($1.51)($1.41)($1.46)
Q2 20181($1.50)($1.50)($1.50)
Q3 20181($1.43)($1.43)($1.43)
Q4 20181($1.43)($1.43)($1.43)

Adamas Pharmaceuticals (NASDAQ ADMS) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/3/2018Q1 2018($1.37)($1.35)$1.71 million$2.55 millionViewN/AView Earnings Details
2/22/2018Q4 2017($1.18)($1.27)$0.84 million$0.57 millionViewN/AView Earnings Details
11/2/2017Q3 2017($1.01)($1.04)$0.03 millionViewN/AView Earnings Details
8/8/2017Q2 2017($0.81)($0.93)$0.03 million$0.02 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.72)($0.72)$0.11 millionViewListenView Earnings Details
2/28/2017Q4($0.80)($0.68)$0.17 million$0.04 millionViewN/AView Earnings Details
11/3/2016Q3 2016($0.83)($0.66)$0.26 million$0.14 millionViewN/AView Earnings Details
8/4/2016Q2 2016($0.71)($0.78)$0.18 million$0.22 millionViewN/AView Earnings Details
5/10/2016Q1($0.76)($0.65)$0.18 millionViewN/AView Earnings Details
2/23/2016Q4($0.81)($0.58)$0.10 million$0.52 millionViewN/AView Earnings Details
11/12/2015Q3($0.79)($0.81)$0.10 million$0.77 millionViewN/AView Earnings Details
8/11/2015Q215($0.67)($0.78)$0.10 million$0.40 millionViewN/AView Earnings Details
5/13/2015Q414($0.74)($0.69)$0.10 million$0.23 millionViewN/AView Earnings Details
3/3/2015Q4 2014$0.64$0.50$30.18 million$30.30 millionViewN/AView Earnings Details
11/4/2014Q314($0.44)($0.57)$0.18 million$0.22 millionViewN/AView Earnings Details
8/7/2014Q214$2.07$0.88$18.75 million$25.15 millionViewN/AView Earnings Details
5/13/2014Q114($0.09)($0.67)$30.60 million$0.1760 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Adamas Pharmaceuticals (NASDAQ:ADMS) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Adamas Pharmaceuticals (NASDAQ ADMS) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 24.60%
Institutional Ownership Percentage: 93.26%
Insider Trading History for Adamas Pharmaceuticals (NASDAQ:ADMS)
Institutional Ownership by Quarter for Adamas Pharmaceuticals (NASDAQ:ADMS)

Adamas Pharmaceuticals (NASDAQ ADMS) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/21/2018Christopher B PrentissCAOSell567$25.98$14,730.6617,758View SEC Filing  
3/21/2018Gregory T WentCEOSell4,541$25.75$116,930.75182,610View SEC Filing  
3/21/2018Rajiv PatniInsiderSell1,252$25.94$32,476.8821,515View SEC Filing  
12/21/2017Jennifer J. RhodesInsiderSell440$32.30$14,212.00View SEC Filing  
6/21/2017Great Point Partners LlcMajor ShareholderSell380,000$17.08$6,490,400.00View SEC Filing  
6/21/2017Jennifer J. RhodesInsiderSell1,041$17.53$18,248.73View SEC Filing  
6/19/2017Great Point Partners LlcMajor ShareholderSell350,000$17.05$5,967,500.00View SEC Filing  
3/21/2017Gregory T WentCEOSell2,807$17.03$47,803.21166,526View SEC Filing  
3/21/2017Rajiv PatniInsiderSell733$17.04$12,490.3213,642View SEC Filing  
3/21/2017William J DawsonCFOSell716$17.02$12,186.3214,284View SEC Filing  
9/16/2016Ix Lp MdvMajor ShareholderBuy62,977$16.48$1,037,860.96View SEC Filing  
9/13/2016Ix Lp MdvMajor ShareholderBuy84,376$15.58$1,314,578.08View SEC Filing  
9/7/2016William W EricsonDirectorBuy60,846$15.68$954,065.28View SEC Filing  
9/6/2016Ix Lp MdvMajor ShareholderBuy50,919$14.79$753,092.01View SEC Filing  
9/6/2016William W EricsonDirectorBuy7,200$15.00$108,000.00View SEC Filing  
9/2/2016William W EricsonDirectorBuy43,719$14.75$644,855.25View SEC Filing  
4/18/2016Natalie McclureSVPSell36,000$18.50$666,000.0021,006View SEC Filing  
12/7/2015Ivan M LieberburgDirectorSell3,000$16.23$48,690.0048,000View SEC Filing  
10/5/2015Ivan M LieberburgDirectorSell3,000$16.75$50,250.0054,000View SEC Filing  
9/8/2015Ivan M LieberburgDirectorSell3,000$19.13$57,390.0057,000View SEC Filing  
7/6/2015Ivan M LieberburgDirectorSell3,000$25.91$77,730.00View SEC Filing  
6/5/2015Natalie McclureSVPSell2,000$18.95$37,900.00View SEC Filing  
5/18/2015Ix Lp MdvMajor ShareholderSell1,643$18.04$29,639.72View SEC Filing  
5/15/2015Richard H BoothDirectorSell1,000$17.85$17,850.00View SEC Filing  
5/14/2015Gregory T WentCEOSell2,728$18.00$49,104.00View SEC Filing  
4/23/2015Gregory T WentCEOSell3,300$18.00$59,400.00View SEC Filing  
4/21/2015Gregory T WentCEOSell962$18.01$17,325.62View SEC Filing  
4/20/2015Gregory T WentCEOSell2,610$18.00$46,980.00View SEC Filing  
4/15/2015Richard H BoothDirectorSell1,000$17.72$17,720.00View SEC Filing  
4/14/2015Gregory T WentCEOSell14,757$7.15$105,512.55View SEC Filing  
4/10/2015William W EricsonDirectorSell37,078$18.56$688,167.68View SEC Filing  
4/6/2015Ivan M LieberburgDirectorSell3,000$17.44$52,320.00View SEC Filing  
4/6/2015Natalie McclureSVPSell2,000$17.44$34,880.00View SEC Filing  
3/19/2015Gregory T WentCEOSell23,088$18.00$415,584.00View SEC Filing  
3/18/2015Ix Lp MdvMajor ShareholderSell11,723$18.02$211,248.46View SEC Filing  
3/16/2015Richard H BoothDirectorSell1,000$17.36$17,360.00View SEC Filing  
3/13/2015Aeris Capital Equity InvestmenMajor ShareholderSell350,000$17.23$6,030,500.00View SEC Filing  
2/17/2015Richard H BoothDirectorSell1,000$16.54$16,540.00View SEC Filing  
2/5/2015Natalie McclureSVPSell2,000$16.87$33,740.00View SEC Filing  
2/2/2015Ivan M LieberburgDirectorSell3,000$16.77$50,310.00View SEC Filing  
1/5/2015Ivan M LieberburgDirectorSell3,000$17.59$52,770.00View SEC Filing  
1/5/2015Natalie McclureSVPSell2,000$17.59$35,180.00View SEC Filing  
12/24/2014Richard H BoothDirectorSell2,000$17.51$35,020.00View SEC Filing  
12/3/2014Aeris Capital Equity InvestmenMajor ShareholderSell111,625$14.51$1,619,678.75View SEC Filing  
12/1/2014Aeris Capital Equity InvestmenMajor ShareholderSell13,615$14.54$197,962.10View SEC Filing  
12/1/2014Natalie McclureSVPSell20,000$14.50$290,000.00View SEC Filing  
11/26/2014Aeris Capital Equity InvestmenMajor ShareholderSell12,500$14.77$184,625.00View SEC Filing  
11/25/2014Aeris Capital Equity InvestmenMajor ShareholderSell10,000$14.85$148,500.00View SEC Filing  
4/15/2014William W EricsonDirectorBuy300,000$16.00$4,800,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Adamas Pharmaceuticals (NASDAQ ADMS) News Headlines

Source:
DateHeadline
Adamas Pharmaceuticals (ADMS) Given Consensus Recommendation of "Buy" by BrokeragesAdamas Pharmaceuticals (ADMS) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - May 24 at 5:43 PM
Adamas Announces Publication of Pharmacokinetic Data for GOCOVRI™ in Clinical PharmacokineticsAdamas Announces Publication of Pharmacokinetic Data for GOCOVRI™ in Clinical Pharmacokinetics
finance.yahoo.com - May 24 at 9:23 AM
Adamas Pharmaceuticals Sees Unusually Large Options Volume (ADMS)Adamas Pharmaceuticals Sees Unusually Large Options Volume (ADMS)
www.americanbankingnews.com - May 24 at 6:42 AM
Adamas Pharmaceuticals (ADMS) Expected to Post Quarterly Sales of $4.80 MillionAdamas Pharmaceuticals (ADMS) Expected to Post Quarterly Sales of $4.80 Million
www.americanbankingnews.com - May 23 at 1:48 AM
 Analysts Anticipate Adamas Pharmaceuticals (ADMS) to Announce -$1.44 EPS Analysts Anticipate Adamas Pharmaceuticals (ADMS) to Announce -$1.44 EPS
www.americanbankingnews.com - May 21 at 11:10 PM
Adamas Pharmaceuticals: Interesting Over The Long TermAdamas Pharmaceuticals: Interesting Over The Long Term
seekingalpha.com - May 18 at 4:44 PM
Adamas Pharmaceuticals (ADMS) PT Raised to Street High $91 at Evercore ISIAdamas Pharmaceuticals (ADMS) PT Raised to Street High $91 at Evercore ISI
www.streetinsider.com - May 11 at 10:12 AM
Zacks Investment Research Downgrades Adamas Pharmaceuticals (ADMS) to HoldZacks Investment Research Downgrades Adamas Pharmaceuticals (ADMS) to Hold
www.americanbankingnews.com - May 9 at 5:08 PM
Adamas Pharmaceuticals (ADMS) Stock Rating Upgraded by Zacks Investment ResearchAdamas Pharmaceuticals (ADMS) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - May 8 at 4:05 PM
FY2021 Earnings Forecast for Adamas Pharmaceuticals Issued By Piper Jaffray (ADMS)FY2021 Earnings Forecast for Adamas Pharmaceuticals Issued By Piper Jaffray (ADMS)
www.americanbankingnews.com - May 7 at 5:20 AM
 Brokerages Expect Adamas Pharmaceuticals (ADMS) Will Post Quarterly Sales of $3.61 Million Brokerages Expect Adamas Pharmaceuticals (ADMS) Will Post Quarterly Sales of $3.61 Million
www.americanbankingnews.com - May 6 at 2:58 AM
Edited Transcript of ADMS earnings conference call or presentation 3-May-18 8:30pm GMTEdited Transcript of ADMS earnings conference call or presentation 3-May-18 8:30pm GMT
finance.yahoo.com - May 4 at 4:46 PM
Adamas Pharmaceuticals (ADMS) Announces Quarterly  Earnings ResultsAdamas Pharmaceuticals (ADMS) Announces Quarterly Earnings Results
www.americanbankingnews.com - May 4 at 4:36 PM
Adamas Pharmaceuticals (ADMS) Expected to Announce Earnings of -$1.53 Per ShareAdamas Pharmaceuticals (ADMS) Expected to Announce Earnings of -$1.53 Per Share
www.americanbankingnews.com - May 4 at 4:00 PM
Adamas Pharmaceuticals (ADMS) Rating Increased to Strong-Buy at ValuEngineAdamas Pharmaceuticals (ADMS) Rating Increased to Strong-Buy at ValuEngine
www.americanbankingnews.com - May 4 at 3:34 PM
Adamas Pharmaceuticals (ADMS) CEO Gregory Went on Q1 2018 Results - Earnings Call TranscriptAdamas Pharmaceuticals' (ADMS) CEO Gregory Went on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 4 at 9:04 AM
Adamas: 1Q Earnings SnapshotAdamas: 1Q Earnings Snapshot
finance.yahoo.com - May 4 at 9:04 AM
Adamas Reports First Quarter 2018 Financial ResultsAdamas Reports First Quarter 2018 Financial Results
finance.yahoo.com - May 3 at 4:41 PM
Adamas Pharmaceuticals (ADMS) Set to Announce Earnings on ThursdayAdamas Pharmaceuticals (ADMS) Set to Announce Earnings on Thursday
www.americanbankingnews.com - May 2 at 8:10 PM
Adamas Pharmaceuticals (ADMS) Raised to "Buy" at BidaskClubAdamas Pharmaceuticals (ADMS) Raised to "Buy" at BidaskClub
www.americanbankingnews.com - May 1 at 9:13 AM
JFs Core Biotech Buys #13: Continued Market Headwinds And How To RespondJF's Core Biotech Buys #13: Continued Market Headwinds And How To Respond
www.msn.com - May 1 at 9:07 AM
Adamas Pharmaceuticals (ADMS) Given Average Recommendation of "Buy" by BrokeragesAdamas Pharmaceuticals (ADMS) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - April 29 at 5:41 PM
Adamas to Announce First Quarter 2018 Financial Results and Host Conference Call on May 3, 2018Adamas to Announce First Quarter 2018 Financial Results and Host Conference Call on May 3, 2018
finance.yahoo.com - April 26 at 4:40 PM
JFs Core Biotech Buys #12: Updates And Introducing Our 18th SelectionJF's Core Biotech Buys #12: Updates And Introducing Our 18th Selection
seekingalpha.com - April 24 at 9:09 AM
Traders Purchase High Volume of Adamas Pharmaceuticals Put Options (ADMS)Traders Purchase High Volume of Adamas Pharmaceuticals Put Options (ADMS)
www.americanbankingnews.com - April 24 at 6:11 AM
3 Things In Biotech, April 22: All These A Companies3 Things In Biotech, April 22: All These 'A' Companies
seekingalpha.com - April 23 at 9:35 AM
Adamas Pharmaceuticals (ADMS) Given a $49.00 Price Target at Piper JaffrayAdamas Pharmaceuticals (ADMS) Given a $49.00 Price Target at Piper Jaffray
www.americanbankingnews.com - April 23 at 9:18 AM
Q3 2018 Earnings Estimate for Adamas Pharmaceuticals (ADMS) Issued By Leerink SwannQ3 2018 Earnings Estimate for Adamas Pharmaceuticals (ADMS) Issued By Leerink Swann
www.americanbankingnews.com - April 23 at 2:12 AM
Adamas Pharma (ADMS) Reports Final Results from Two-Year Phase 3 Open-Label Study of GOCOVRIAdamas Pharma (ADMS) Reports Final Results from Two-Year Phase 3 Open-Label Study of GOCOVRI
www.streetinsider.com - April 21 at 9:01 AM
Adamas Pharmaceuticals (ADMS) Upgraded to "Hold" by BidaskClubAdamas Pharmaceuticals (ADMS) Upgraded to "Hold" by BidaskClub
www.americanbankingnews.com - April 21 at 7:06 AM
Mizuho Reiterates "Buy" Rating for Adamas Pharmaceuticals (ADMS)Mizuho Reiterates "Buy" Rating for Adamas Pharmaceuticals (ADMS)
www.americanbankingnews.com - April 20 at 7:46 AM
Adamas Pharmaceuticals Inc’s (NASDAQ:ADMS) Earnings Dropped -49.01%, How Did It Fare Against The Industry?Adamas Pharmaceuticals Inc’s (NASDAQ:ADMS) Earnings Dropped -49.01%, How Did It Fare Against The Industry?
finance.yahoo.com - April 19 at 4:49 PM
Adamas Pharmaceuticals (ADMS) Expected to Announce Quarterly Sales of $1.68 MillionAdamas Pharmaceuticals (ADMS) Expected to Announce Quarterly Sales of $1.68 Million
www.americanbankingnews.com - April 19 at 3:06 AM
Q1 2018 EPS Estimates for Adamas Pharmaceuticals Decreased by Analyst (ADMS)Q1 2018 EPS Estimates for Adamas Pharmaceuticals Decreased by Analyst (ADMS)
www.americanbankingnews.com - April 18 at 7:58 AM
JFs Core Biotech Buys #11: Positive News For Several Holdings, A Change To Benchmarks And Introducing Our 17th ...JF's Core Biotech Buys #11: Positive News For Several Holdings, A Change To Benchmarks And Introducing Our 17th ...
seekingalpha.com - April 17 at 4:46 PM
 Brokerages Anticipate Adamas Pharmaceuticals (ADMS) Will Announce Earnings of -$1.38 Per Share Brokerages Anticipate Adamas Pharmaceuticals (ADMS) Will Announce Earnings of -$1.38 Per Share
www.americanbankingnews.com - April 17 at 1:19 PM
Adamas Pharmaceuticals (ADMS) PT Set at $45.00 by CowenAdamas Pharmaceuticals (ADMS) PT Set at $45.00 by Cowen
www.americanbankingnews.com - April 11 at 7:53 PM
Adamas Pharmaceuticals (ADMS) Upgraded to "Sell" by BidaskClubAdamas Pharmaceuticals (ADMS) Upgraded to "Sell" by BidaskClub
www.americanbankingnews.com - April 9 at 10:19 PM
3 Things In Biotech, April 5: Pfizers Game Changer, Adamas Tackles MS, Aeglea Dives Into Small Cell3 Things In Biotech, April 5: Pfizer's Game Changer, Adamas Tackles MS, Aeglea Dives Into Small Cell
seekingalpha.com - April 6 at 9:29 AM
Adamas Pharmaceuticals (ADMS) to Post Q1 2018 Earnings of ($1.41) Per Share, Leerink Swann ForecastsAdamas Pharmaceuticals (ADMS) to Post Q1 2018 Earnings of ($1.41) Per Share, Leerink Swann Forecasts
www.americanbankingnews.com - April 6 at 6:48 AM
Adamas Pharma (ADMS) Reports 1st Patient Enrolled in Phase 3 Trial of ADS-5102 in Multiple Sclerosis Patients with Walking ImpairmentAdamas Pharma (ADMS) Reports 1st Patient Enrolled in Phase 3 Trial of ADS-5102 in Multiple Sclerosis Patients with Walking Impairment
www.streetinsider.com - April 5 at 9:31 AM
Adamas Pharmaceuticals (ADMS) Given Average Rating of "Buy" by BrokeragesAdamas Pharmaceuticals (ADMS) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - April 4 at 5:34 PM
Adamas Pharmaceuticals (ADMS) Now Covered by Leerink SwannAdamas Pharmaceuticals (ADMS) Now Covered by Leerink Swann
www.americanbankingnews.com - April 4 at 9:30 AM
Adamas Pharmaceuticals (ADMS) Upgraded at ValuEngineAdamas Pharmaceuticals (ADMS) Upgraded at ValuEngine
www.americanbankingnews.com - April 3 at 8:10 PM
Adamas Announces First Patient Enrolled in Phase 3 Trial of ADS-5102 in Multiple Sclerosis Patients with Walking ImpairmentAdamas Announces First Patient Enrolled in Phase 3 Trial of ADS-5102 in Multiple Sclerosis Patients with Walking Impairment
finance.yahoo.com - April 3 at 9:25 AM
$1.37 Million in Sales Expected for Adamas Pharmaceuticals Inc (ADMS) This Quarter$1.37 Million in Sales Expected for Adamas Pharmaceuticals Inc (ADMS) This Quarter
www.americanbankingnews.com - April 2 at 3:06 AM
Adamas Pharmaceuticals (ADMS) Price Target Raised to $48.00Adamas Pharmaceuticals (ADMS) Price Target Raised to $48.00
www.americanbankingnews.com - April 1 at 9:41 AM
Zacks: Brokerages Anticipate Adamas Pharmaceuticals Inc (ADMS) Will Post Earnings of -$1.37 Per ShareZacks: Brokerages Anticipate Adamas Pharmaceuticals Inc (ADMS) Will Post Earnings of -$1.37 Per Share
www.americanbankingnews.com - March 31 at 1:20 PM
Adamas Pharmaceuticals (ADMS) Upgraded at Zacks Investment ResearchAdamas Pharmaceuticals (ADMS) Upgraded at Zacks Investment Research
www.americanbankingnews.com - March 30 at 9:28 PM
Adamas Pharmaceuticals (ADMS) Downgraded by BidaskClub to SellAdamas Pharmaceuticals (ADMS) Downgraded by BidaskClub to Sell
www.americanbankingnews.com - March 27 at 5:10 PM

SEC Filings

Adamas Pharmaceuticals (NASDAQ:ADMS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Adamas Pharmaceuticals (NASDAQ:ADMS) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Adamas Pharmaceuticals (NASDAQ ADMS) Stock Chart for Monday, May, 28, 2018

Loading chart…

This page was last updated on 5/28/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.